tuberculosis vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.

Top Publications

  1. ncbi Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
  2. ncbi Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
  3. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
  4. ncbi Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis
    H Martin Vordermeier
    TB Research Group, VLA Weybridge, New Haw, Addlestone, Surrey, United Kingdom
    Infect Immun 77:3364-73. 2009
  5. ncbi Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Laith J Abu-Raddad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:13980-5. 2009
  6. ncbi New vaccines for tuberculosis
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Lancet 375:2110-9. 2010
  7. ncbi Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells
    Thomas Lindenstrøm
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Immunol 182:8047-55. 2009
  8. ncbi Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
  9. ncbi Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
  10. ncbi Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008

Research Grants

  1. MYCOBACTERIAL GENES ANTIGENS AND VACCINES
    Barry Bloom; Fiscal Year: 2000
  2. DIETARY DEFICIENCIES AND TUBERCULOSIS VACCINE EFFICIENCY
    David McMurray; Fiscal Year: 2004
  3. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2010
  4. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2009
  5. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    CHERYL LIANE DAY; Fiscal Year: 2010
  6. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    Cheryl Day; Fiscal Year: 2009
  7. POPULATION-BASED MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS
    Philip Hopewell; Fiscal Year: 2000
  8. LATENCY AND REACTIVATION TUBERCULOSIS
    William Bishai; Fiscal Year: 2002
  9. LATENCY AND REACTIVATION TUBERCULOSIS
    YUKARI MANABE; Fiscal Year: 2006
  10. Heat Shock Protein based vaccine for Tuberculosis
    ANNIE MO; Fiscal Year: 2003

Detail Information

Publications219 found, 100 shown here

  1. ncbi Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals
    Clare R Sander
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK
    Am J Respir Crit Care Med 179:724-33. 2009
    ..An effective new tuberculosis (TB) vaccine regimen must be safe in individuals with latent TB infection (LTBI) and is a priority for global health care...
  2. ncbi Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells
    Thomas J Scriba
    South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, University of Cape Town, Observatory, South Africa
    Eur J Immunol 40:279-90. 2010
    ..This includes induction of novel Th1-cell populations that have not been previously described in humans...
  3. ncbi IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
    Shabaana A Khader
    Trudeau Institute, Saranac Lake, New York 12983, USA
    Nat Immunol 8:369-77. 2007
    ....
  4. ncbi Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis
    H Martin Vordermeier
    TB Research Group, VLA Weybridge, New Haw, Addlestone, Surrey, United Kingdom
    Infect Immun 77:3364-73. 2009
    ..These findings also have implications for human tuberculosis vaccine development...
  5. ncbi Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
    Laith J Abu-Raddad
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:13980-5. 2009
    ..Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people...
  6. ncbi New vaccines for tuberculosis
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Lancet 375:2110-9. 2010
    ..Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs...
  7. ncbi Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells
    Thomas Lindenstrøm
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    J Immunol 182:8047-55. 2009
    ....
  8. ncbi Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, United Kingdom
    Clin Vaccine Immunol 17:1066-73. 2010
    ..These data highlight the intricate balance of effector and regulatory immune responses induced by vaccination and that preexisting immunity to mycobacterial antigens may affect the composition of vaccine-induced T-cell subsets...
  9. ncbi Novel prophylactic and therapeutic vaccine against tuberculosis
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, 1180 Nagasone, Kitaku, Sakai, Osaka 591 8555, Japan
    Vaccine 27:3267-70. 2009
    ..These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials...
  10. ncbi Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  11. ncbi Recent findings in immunology give tuberculosis vaccines a new boost
    Stefan H E Kaufmann
    Max Planck Institute for Infection Biology, Department of Immunology, Schumannstrasse 21 22, 10117 Berlin, Germany
    Trends Immunol 26:660-7. 2005
    ..For clinical trials, biomarkers need to be defined with T cells alternating between lung and periphery as prime indicator cells...
  12. ncbi The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans
    Kenneth von Eschen
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Hum Vaccin 5:475-82. 2009
    ..This first trial in humans found Mtb72F/AS02A to have an acceptable tolerability, to be immunogenic in healthy adults and warrants further development of the vaccine...
  13. ncbi Tuberculosis vaccine research: the impact of immunology
    Lewellys F Barker
    Aeras Global TB Vaccine Foundation, Rockville, MD 20850, USA
    Curr Opin Immunol 21:331-8. 2009
    ....
  14. ncbi Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates
    Michelle H Larsen
    Albert Einstein College of Medicine, Bronx, NY 1461, USA
    Vaccine 27:4709-17. 2009
    ..BCG vaccinates had reduced tuberculosis-associated pathology and improved clinical scores as compared to saline and mc(2)6030 vaccinates, but survival did not differ among the groups...
  15. ncbi Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis
    Lisa Goldsack
    Malaghan Institute of Medical Research, P O Box 7060, Wellington South 6021, New Zealand
    Tuberculosis (Edinb) 87:465-73. 2007
    ..A comprehensive understanding of the requirements for protective memory immunity to tuberculosis is essential for the development of an effective vaccine...
  16. ncbi Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa
    Roger H Brookes
    Bacterial Diseases Programme, Tuberculosis Division, Medical Research Council Laboratories, Fajara, Banjul, The Gambia
    PLoS ONE 3:e2921. 2008
    ..We assessed the safety and immunogenicity of this new vaccine in West African volunteers...
  17. ncbi Development of vaccines to control bovine tuberculosis in cattle and relationship to vaccine development for other intracellular pathogens
    Bryce M Buddle
    AgResearch, Wallaceville Animal Research Centre, P O Box 40063, Upper Hutt, New Zealand
    Int J Parasitol 33:555-66. 2003
    ..bovis genome have provided opportunities for the rational development of improved tuberculosis vaccines. A number of new tuberculosis vaccines including attenuated M...
  18. ncbi TB vaccines: current status and future perspectives
    Claus Aagaard
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Immunol Cell Biol 87:279-86. 2009
    ..Three such fusion proteins are currently in clinical trials, the two most advanced have already passed phase I trials and are entering phase II...
  19. ncbi Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity
    Marcus A Horwitz
    Department of Medicine, CHS 37 121, School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1688, USA
    Vaccine 24:443-51. 2006
    ..This study demonstrates that a very low inoculum of rBCG30 organisms has the capacity to induce strong protective immunity against tuberculosis and that rBCG30 is an extremely potent delivery system for mycobacterial antigens...
  20. ncbi Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein
    Yasir A W Skeiky
    Corixa Corp, Seattle, WA 98104, USA
    J Immunol 172:7618-28. 2004
    ..tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans...
  21. ncbi Tuberculosis: vaccines in the pipeline
    Lan H Ly
    Department of Microbial and Molecular Pathogenesis, College of Medicine, Texas A and M University System Health Science Center, College Station, TX 77843 1114, USA
    Expert Rev Vaccines 7:635-50. 2008
    ..Some of these new vaccines may eventually be recommended for travelers to TB high-burden countries. This paper summarizes the progress of vaccine candidates in animal models to improve, replace or augment BCG vaccination...
  22. ncbi Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults
    Isabel Leroux-Roels
    Center for Vaccinology, Ghent University Hospital, De Pintelaan 185, B 9000 Ghent, Belgium
    Clin Vaccine Immunol 17:1763-71. 2010
    ..In conclusion, Mtb72F/AS02(A) is clinically well tolerated and is highly immunogenic in TB-naïve adults. The 10- and 40-μg Mtb72F/AS02(A) vaccines show comparable safety and immunogenicity profiles...
  23. ncbi Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?
    Graham A W Rook
    Centre for Infectious Disease and International Health, University College London, Windeyer Institute of Medical Sciences, London W1T 4JF, UK
    Vaccine 23:2115-20. 2005
    ..A successful vaccine, rather than driving a Th1 response, might need to suppress this pre-existing subversive Th2-like component...
  24. ncbi A comparison of IFNgamma detection methods used in tuberculosis vaccine trials
    Natalie E R Beveridge
    Jenner Institute, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
    Tuberculosis (Edinb) 88:631-40. 2008
    ..Future tuberculosis vaccine trials and immunology studies should ideally include a combination of ex vivo and cultured assays to ensure a thorough and multifaceted evaluation of the immune response is achieved...
  25. ncbi rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector
    Isabelle Magalhaes
    Microbiology, Tumor and Cell Biology Center, Karolinska Institutet, Solna, Sweden
    PLoS ONE 3:e3790. 2008
    ..4, for the capacity to induce antigen-specific cellular immune responses in rhesus macaques (Macaca mulatta). Control animals received diluent (3 animals)...
  26. ncbi The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection
    Ela Martin
    Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW, Australia
    Immunology 109:308-14. 2003
    ..avium infection above that achieved by BCG, and this strategy may improve the efficacy of subunit vaccines against M. leprae and M. tuberculosis...
  27. ncbi Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    APMIS 117:440-57. 2009
    ..In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies...
  28. ncbi The second Geneva Consensus: Recommendations for novel live TB vaccines
    K B Walker
    HPA NIBSC, Blanche Lane, South Mimms, Potters Bar, UK
    Vaccine 28:2259-70. 2010
    ..v. Consider requirements and associated issues related to the use of these new vaccines within an existing BCG vaccination programme...
  29. ncbi Update on research and development pipeline: tuberculosis vaccines
    Belinda Beresford
    Aeras Global TB Vaccine Foundation, Rockville, Maryland 20850, USA
    Clin Infect Dis 50:S178-83. 2010
    ....
  30. ncbi Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine
    Steven C Derrick
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Immunology 120:192-206. 2007
    ....
  31. ncbi DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation
    Shigeto Yoshida
    Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, Tochigi 329 0498, Japan
    Vaccine 24:1191-204. 2006
    ..tuberculosis. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine...
  32. ncbi Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding
    Eung Jun Im
    Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, United Kingdom
    J Virol 81:9408-18. 2007
    ....
  33. ncbi Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI
    C Vilaplana
    Experimental Tuberculosis Unit, Germans Trias I Pujol Health Science Research Institute Foundation, Autonomous University of Barcelona, Crtra del Canyet s n, Edifici Recerca, Catalonia, Spain
    Vaccine 28:1106-16. 2010
    ..These results support the feasibility of future evaluation, to be targeted at subjects with latent tuberculosis infection (LTBI)...
  34. ncbi Current status of TB vaccines
    Umesh Datta Gupta
    National JALMA Institute for Leprosy and Other Mycobacterial Disease ICMR, P Box No 1101, Tajganj, Agra 282001, India
    Vaccine 25:3742-51. 2007
    ..These recent advances in the clinical testing of new TB vaccines are very exciting and promising. However, there is a need to continue the search for additional vaccine candidates or vaccination strategies...
  35. ncbi Prime-boost immunisation strategies for tuberculosis
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Microbes Infect 7:962-7. 2005
    ..Using BCG as the priming immunisation in such a heterologous prime-boost strategy is a practical solution, which allows the beneficial effects of BCG in children to be maintained...
  36. ncbi Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
    Kathryn T Whelan
    Jenner Institute, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 4:e5934. 2009
    ....
  37. ncbi Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c)
    Marta Romano
    Mycobacterial Immunology, Pasteur Institute, Wetenschappelijk Instituut voor Volksgezondheid, Brussels, Belgium
    Vaccine 26:6053-63. 2008
    ..Taken together these results indicate that PPE44 of M. tuberculosis is a protective antigen that could be included in novel subunit TB vaccines and that warrants further analysis...
  38. ncbi Preclinical testing of new vaccines for tuberculosis: a comprehensive review
    Ian M Orme
    Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Lake Street, Fort Collins, CO 80523, USA
    Vaccine 24:2-19. 2006
    ..In addition, no standardized models of safety/toxicology exist as yet, which will be needed before extensive clinical development of the new vaccines...
  39. ncbi Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1
    Helen A Fletcher
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Vaccine 26:5269-75. 2008
    ..This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines...
  40. ncbi Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model
    Yoko Kita
    Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka 591-8555, Japan
    Vaccine 23:2132-5. 2005
    ..Most importantly, HSP65+IL-12/HVJ resulted in an increased survival for over a year. This is the first report of successful DNA vaccination and recombinant BCG vaccination against M. tuberculosis in the monkey model...
  41. ncbi Potent role of vaccines prepared from macrophages infected with live bacteria in protection against Mycobacterium tuberculosis and Salmonella typhimurium infections
    Naresh Sharma
    Immunology Laboratory, Institute of Microbial Technology, Chandigarh, India
    J Infect Dis 190:107-14. 2004
    ..tuberculosis. This vaccination strategy worked successfully for tuberculosis but also showed a significant decrease in mortality of mice challenged with live S. typhimurium...
  42. ncbi Potential public health impact of new tuberculosis vaccines
    Elad Ziv
    University of California-San Francisco, San Francisco, California, USA
    Emerg Infect Dis 10:1529-35. 2004
    ..Even widely deployed and highly effective (50%-90% efficacy) pre- or postexposure vaccines would only be able to reduce the number of TB cases by one third. We discuss the health policy implications of our analyses...
  43. ncbi Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain
    D Aguilar
    Experimental Pathology Section, Department of Pathology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico
    Clin Exp Immunol 147:330-8. 2007
    ..The levels of protection conferred by vaccination with M. tuberculosis SO2 or with M. bovis BCG were similar, as measured by granuloma coalescence and pneumonia in addition to growth reduction of M. tuberculosis H37Rv...
  44. ncbi Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, DK 2300 Copenhagen, Denmark
    J Immunol 177:6353-60. 2006
    ..tb in LTK63/Ag85B-ESAT-6-boosted mice, compared with BCG-vaccinated animals. Thus, LTK63/Ag85B-ESAT-6 represents an efficient preventive vaccine against tuberculosis with a strong ability to boost prior BCG immunity...
  45. ncbi Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon
    Katarina Radosevic
    Crucell Holland BV, Archimedesweg 4 6, 2333 CN Leiden, The Netherlands
    Infect Immun 75:4105-15. 2007
    ..These results unify conflicting reports on the relative importance of CD4 versus CD8 T-cell responses in protection and emphasize the key role of IFN-gamma...
  46. ncbi Development of new tuberculosis vaccines: a global perspective on regulatory issues
    Michael J Brennan
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland, United States of America
    PLoS Med 4:e252. 2007
  47. ncbi Tuberculosis vaccines: past, present and future
    Carlos Martin
    Department of Microbiology and Public Health, Faculty of Medicine, University of Zaragoza, Spain
    Curr Opin Pulm Med 12:186-91. 2006
    ..This review will outline the most promising tuberculosis vaccine candidates from selected publications...
  48. ncbi The immunology of bovine tuberculosis and progression toward improved disease control strategies
    J McNair
    Veterinary Sciences Division, Agri Food and Biosciences Institute, Stoney Road, Stormont, Belfast BT4 3SD, Northern Ireland, United Kingdom
    Vaccine 25:5504-11. 2007
    ..This paper describes those recent advances which may lead to the introduction of improved disease control strategies...
  49. ncbi Failure of a Mycobacterium tuberculosis DeltaRD1 DeltapanCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis bacille Calmette Guerin
    W Ray Waters
    National Animal Disease Center, Agricultural Research Service, US Department of Agriculture, 2300 Dayton Avenue, Ames, IA 50010, USA
    Vaccine 25:7832-40. 2007
    ..The calf sensitization and challenge model provides an informative screen for candidate tuberculosis vaccines before their evaluation in costly non-human, primates.
  50. ncbi Human immune recognition-based multicomponent subunit vaccines against tuberculosis
    S B Sable
    Dept of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    Eur Respir J 25:902-10. 2005
    ..The results of this study indicate that high T-helper cell type 1 response-inducing polypeptides selected on the basis of human immune recognition do not necessarily impart protection during vaccination experiments...
  51. ncbi Next generation: tuberculosis vaccines that elicit protective CD8+ T cells
    Samuel M Behar
    Brigham and Women s Hospital and Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Smith Building, Room 516C, One Jimmy Fund Way, Boston, MA 02115, USA
    Expert Rev Vaccines 6:441-56. 2007
    ..The synergy between CD4+ and CD8+ T cells suggests that a vaccine that elicits both T-cell subsets has the best chance at preventing tuberculosis...
  52. ncbi Current progress in tuberculosis vaccine development
    Ian M Orme
    Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
    Vaccine 23:2105-8. 2005
    ....
  53. ncbi The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium
    G W de Lisle
    AgResearch, Wallaceville Animal Research Centre, PO Box 40 063, Upper Hutt, New Zealand
    Tuberculosis (Edinb) 85:73-9. 2005
    ..Presensitization of guinea pigs by the oral administration of M. avium+ provides a model for testing vaccines under conditions where the efficacy of BCG has been compromised by prior sensitization with environmental mycobacteria...
  54. ncbi Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine
    Masaji Okada
    Clinical Research Center, National Hospital Organization Kinki chuo Chest Medical Center, Kita ku, Sakai City, Osaka, Japan
    Hum Vaccin 6:297-308. 2010
    ....
  55. ncbi Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis
    Xiao Yan Yang
    Chinese Evidence Based Medicine Center The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
    J Infect 60:320-30. 2010
    ..To evaluate the effectiveness and safety of Mycobacterium vaccae (MV) in prevention of tuberculosis (TB) among high risk people...
  56. ncbi Towards new tuberculosis vaccines
    Stefan Svenson
    Department of Clinical Research and Education, South Hospital, Karolinska Institutet, Stockholm, Sweden
    Hum Vaccin 6:309-17. 2010
    ..The live attenuated Bacillus Calmette-Guérin (BCG) vaccine which is the only currently available TB vaccine does not confer any significant protection against the most common and contagious form of TB-adult pulmonary TB...
  57. ncbi T cells in mycobacterial infection and disease
    Andrea M Cooper
    The Trudeau Institute, Inc, Saranac Lake, NY 12983, USA
    Curr Opin Immunol 21:378-84. 2009
    ..The integration of the T cell functional data with the consequences of infection should improve rational vaccine design...
  58. ncbi Perspectives on clinical and preclinical testing of new tuberculosis vaccines
    Arthur M Dannenberg
    Center for Tuberculosis Research, Johns Hopkins Medical Institutions, Baltimore, Maryland MD 21205, USA
    Clin Microbiol Rev 23:781-94. 2010
    ..Such critical antigens would increase the host's ability to neutralize key components of M. tuberculosis that enable it to survive in both laboratory animals and humans...
  59. ncbi Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
    Alexander S Pym
    , Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris, Cedex 15, France
    Mol Microbiol 46:709-17. 2002
    ..Knocking-in five other RD loci did not affect the virulence of BCG. This study describes a genetic lesion that contributes to safety and opens new avenues for vaccine development...
  60. ncbi Modelling the effects of pre-exposure and post-exposure vaccines in tuberculosis control
    C P Bhunu
    Modelling Biomedical Systems Research Group, Department of Applied Mathematics, National University of Science and Technology, P O Box AC 939 Ascot, Bulawayo, Zimbabwe
    J Theor Biol 254:633-49. 2008
    ....
  61. ncbi Envisioning future strategies for vaccination against tuberculosis
    Stefan H E Kaufmann
    Stefan H E Kaufmann is at the Max Planck Institute for Infection Biology, Department of Immunology, Schumannstrasse 21 22, 10117 Berlin, Germany
    Nat Rev Immunol 6:699-704. 2006
    The design of tuberculosis vaccines has entered a new era...
  62. ncbi Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis
    Michael Santosuosso
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Center for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Infect Immun 74:4634-43. 2006
    ..Our study demonstrates that intranasal administration of AdAg85A represents an effective way to boost immune protection by parenteral BCG vaccination...
  63. ncbi Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation
    Stig Tollefsen
    Institute of Immunology, University of Oslo, Norway
    Vaccine 20:3370-8. 2002
    ..We conclude that DNA immunisation in combination with electroporation can significantly improve the immunogenicity of plasmid-based DNA vaccines...
  64. ncbi Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice
    Julie A McMurry
    EpiVax Inc, 146 Clifford Street, Providence RI 02903, USA
    Curr Mol Med 7:351-68. 2007
    ..These experiments illustrate the use of immuno-informatics tools for vaccine development and describe a pathway for the development of a more effective, epitope-driven, immunotherapeutic vaccine for TB...
  65. ncbi DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice
    X Fan
    Laboratory of Biosafety, Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    Scand J Immunol 66:523-8. 2007
    ..These results suggested that the combination of DNA-E6 and BCG vaccination could be a better strategy against M. tuberculosis infections in human...
  66. ncbi Prospects for a novel vaccine against tuberculosis
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Artillerivej 5, 2300 Copenhagen S, Denmark
    Vet Microbiol 112:163-9. 2006
    ..This has resulted in the identification of a large number of antigens with potential in tuberculosis vaccines. The next phase of this work has now started--putting the most relevant molecules back together as fusion ..
  67. ncbi Vaccination with a Sindbis virus-based DNA vaccine expressing antigen 85B induces protective immunity against Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology, Building 29 Room 511, CBER FDA, 29 Lincoln Dr, Bethesda, MD 20892, USA
    Infect Immun 73:7727-35. 2005
    ..These data show that immunization with Sin85B offers protection similar to BCG in a murine model of pulmonary tuberculosis and suggest that Sin85B-induced protection is dependent upon both innate and acquired immune mechanisms...
  68. ncbi Vaccines for tuberculosis: novel concepts and recent progress
    T Mark Doherty
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Clin Microbiol Rev 18:687-702. 2005
    ..This provides a background for describing the new generation of vaccines designed to supplement or replace the current vaccine and the different approaches they take to stimulate immunity against M. tuberculosis...
  69. ncbi [Protective efficacy of DNA vaccines encoding mycobacterium tuberculosis Ag85B protein]
    Xiong lin Fan
    Department of Microbiology, Fourth Military Medical University, Xi an 710032, China
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19:90-2. 2003
    ..To explore protective efficacy of pTB30m and pTB30s encoding Ag85B protein against infection with M. tuberculosis H (37)R (v)...
  70. ncbi Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination
    Sang-Jun Ha
    Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science and Technology, Hyoja-dong, Pohang, Korea
    Infect Immun 74:4954-9. 2006
    ..The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis...
  71. ncbi Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis
    James A Triccas
    Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia
    Immunol Cell Biol 80:346-50. 2002
    ..tuberculosis infection. Therefore co-administration of plasmid-encoded cytokines provides a potential method for optimizing the protective efficacy of DNA vaccination against tuberculosis...
  72. ncbi Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis
    James A Triccas
    Microbial Pathogenesis and Immunity Group, Discipline of Infectious Diseases and Immunology, University of Sydney, Sydney, Australia
    Infect Immun 75:5368-75. 2007
    ..These results demonstrate the potential of in vivo targeting of DCs to improve antimycobacterial vaccine efficacy...
  73. ncbi Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis
    L D Aguilar
    Experimental Pathology Section, Department of Pathology, , Vasco de Quiroga 15, Tlalpan, Mexico City CP-14000, Mexico
    Vaccine 24:2333-42. 2006
    ....
  74. ncbi Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis
    Antonia Isabel Castillo-Rodal
    , , Facultad de Medicina, , Circuito Escolar s/n, , D.F,
    Infect Immun 74:1718-24. 2006
    ..Contemporary BCG substrains induce a wide range of protection in this animal model. These data can help in the selection of the best vaccine for human immunization and for the development of novel recombinant BCG-based vaccine...
  75. ncbi Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis
    Thomas Bennekov
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Eur J Immunol 36:3346-55. 2006
    ....
  76. ncbi The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice
    Carla Palma
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Rome, Italy
    Cell Microbiol 9:1455-65. 2007
    ..They also suggest that Ag85B protein secreted during MTB infection could be involved in the instability of protective anti-tuberculosis immune response, and actually concur to disease progression...
  77. ncbi A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens
    Ajay Grover
    Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    Microbes Infect 8:2390-9. 2006
    ..These results show the protective potential of the multivalent DNA vaccine formulation used in this study...
  78. ncbi Unique model of dormant infection for tuberculosis vaccine development
    Suely S Kashino
    The Forsyth Institute, 140 The Fenway, Boston, MA, 02115-3799, USA
    Clin Vaccine Immunol 13:1014-21. 2006
    ..tuberculosis strain 18b constitutes a simple and attractive animal model for evaluation of antituberculosis vaccines in the context of an M. tuberculosis-presensitized host, a prevailing condition among humans in need of a vaccine...
  79. ncbi Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis
    Manuela Pardini
    Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanit, Rome, Italy
    FEMS Microbiol Lett 262:210-5. 2006
    ..97 log10 CFU decrease). Multipromoter plasmids, which permit the reduction of the total amount of DNA injected, can be useful for DNA vaccination against tuberculosis...
  80. ncbi The RD1-encoded antigen Rv3872 of Mycobacterium tuberculosis as a potential candidate for serodiagnosis of tuberculosis
    P Mukherjee
    Department of Chemistry, Bose Institute, Kolkata 700 009, India
    Clin Microbiol Infect 13:146-52. 2007
    ....
  81. ncbi Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration
    Pramod K Giri
    Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    FEMS Immunol Med Microbiol 47:233-41. 2006
    ..These results suggest that mucosal vaccination via the intranasal route is of importance in the development of vaccine for tuberculosis...
  82. ncbi Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis
    Shi Chang-hong
    Lab Animal Center, The Fourth Military Medical University, Xi an, China
    DNA Cell Biol 27:199-207. 2008
    Genetic immunity is a new promising approach for the development of novel tuberculosis vaccines. In this study, it is shown that DNA vaccines expressing the fusion protein of antigen 85B (Ag85B) and early secreted antigenic target 6-kDa ..
  83. ncbi Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3
    Marta Romano
    Mycobacterial Immunology, Pasteur Institute, Wetenschappelijk Instituut voor Volksgezondheid, Brussels, Belgium
    Immunology 118:321-32. 2006
    ..This may have implications for future combination vaccines using Ag85...
  84. ncbi Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice
    Ying Xu
    State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, China
    FEMS Immunol Med Microbiol 51:480-7. 2007
    ..tuberculosis infection compared with others in organ bacterial loads, lung histopathology and net weight gain or loss. The results suggested that rBCG-AEI is a potential candidate for further study...
  85. ncbi Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics
    P J Cockle
    TB Research Group, Department of Bacterial Diseases, Veterinary Laboratories Agency-Weybridge, New Haw, Addlestone, United Kingdom
    Infect Immun 70:6996-7003. 2002
    ..vaccination and infection, as well as the identification of subunit vaccine candidates for improved tuberculosis vaccines, is a research priority. In the present study, we applied comparative genomics to identify M...
  86. ncbi Prospects for new vaccines against tuberculosis
    Lise Brandt
    Colorado State University, Fort Collins, USA
    Biotechniques 33:1098, 1100, 1102. 2002
  87. ncbi Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  88. ncbi Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis
    Hans Joachim Mollenkopf
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    Infect Immun 72:6471-9. 2004
    ..Furthermore, our experiments show that heterologous prime-boost vaccination with a defined antigen boost "on top" of a BCG primer provides superior protection against tuberculosis over vaccination with BCG alone...
  89. ncbi Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83
    D H Yu
    The National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing, China
    Gene Ther 15:652-9. 2008
    ..001). These results suggest that the combined DNA vaccine along with conventional TB chemotherapy has strong potential for TB immunotherapy and may provide new alternatives to control the disease...
  90. ncbi RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection
    Tian Xue
    Mycobacterial Division, National Institute for Medical Research, London NW7 1AA, UK
    Infect Immun 72:6324-9. 2004
    ..This novel approach avoids some of the drawbacks of DNA vaccines and illustrates the potential for developing new antimycobacterial immunization strategies...
  91. ncbi [A study of the protective effect of the DNA vaccine encoding tubercle antigen 85B with MPT64 in mice challenged with Mycobacterium tuberculosis]
    Xu-Dong Luo
    Department of Microbiology, Chongqing University of Medical Sciences, Chongqing 400016, China
    Zhonghua Jie He He Hu Xi Za Zhi 27:611-6. 2004
    ..CONCLUSION: The protective effect of BCG was more significant than the other groups, while the effect of pcDNA/Ag85B + pcDNA/MPT64 was better than other DNA vaccines...
  92. ncbi Vaccination with DNA vaccines encoding MPB70 or MPB83 or a MPB70 DNA prime-protein boost does not protect cattle against bovine tuberculosis
    D N Wedlock
    AgResearch, Wallaceville Animal Research Centre, P O Box 40063, Upper Hutt, New Zealand
    Tuberculosis (Edinb) 83:339-49. 2003
    ..Bovine tuberculosis is a problem in a number of countries and protection of cattle by vaccination could be an important control strategy...
  93. ncbi Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis
    Ce Tang
    Division of Host Defense, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
    J Infect Dis 197:1263-74. 2008
    ..tuberculosis. Thus, rBCG-Ag85B-IL15 vaccination capable of inducing efficient cell-mediated immunity might be used as an effective vaccine for tuberculosis...
  94. ncbi Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model
    Anja W Olsen
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    Infect Immun 72:6148-50. 2004
    ..The protection was manifested as delayed clinical illness and prolonged survival. Neither Ag85B nor ESAT-6 (independently or as a cocktail) induced significant protection in this model...
  95. ncbi [The study on the Mycobacterium tuberculosis antigen 85 complex and its application in the future]
    Yu Lu
    Zhonghua Jie He He Hu Xi Za Zhi 26:481-4. 2003
  96. ncbi Protection of mice with a divalent tuberculosis DNA vaccine encoding antigens Ag85B and MPT64
    Xia Tian
    The National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing, China
    Acta Biochim Biophys Sin (Shanghai) 36:269-76. 2004
    ..We conclude that our divalent DNA vaccine may be a better choice for controlling tuberculosis disease in animals...
  97. ncbi Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG
    R Al-Attiyah
    Department of Microbiology, Faculty of Medicine, Kuwait University, Safat, Kuwait
    Infect Immun 76:4190-8. 2008
    ....
  98. ncbi Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
    Priscille Brodin
    , INSERM E0352, Institut Pasteur, Paris, France
    J Infect Dis 190:115-22. 2004
    ..microti alone or with BCG. The M. microti OV254::RD1-2F9 vaccine was less virulent and persistent in mice and than was BCG::RD1-2F9 may represent a safer alternative to BCG::RD1-2F9...
  99. ncbi Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis
    Steven C Derrick
    Laboratory of Mycobacterial Diseases and Cellular Immunology. Division of Veterinary Services, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 72:1685-92. 2004
    ..The substantial CD8-mediated protective immunity that was generated in the absence of CD4 cells suggests that it may be possible to develop effective TB vaccines for use in HIV-infected populations...
  100. ncbi The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response
    Carla Palma
    Department of Infectious, Parasitic and Immune Mediated Diseases, Istituto Superiore di Sanita, Viale Regina Elena, 299 00161 Rome, Italy
    Vaccine 26:4237-43. 2008
    ..The recovery of protection through a down-modulation of antigen-specific IFN-gamma response by an adjuvant is a novel finding which could be of relevance in tuberculosis vaccination...
  101. ncbi Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
    Jun Wang
    Department of Pathology and Molecular Medicine and Division of Infectious Diseases, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    J Immunol 173:6357-65. 2004
    ..Our study also lends strong evidence that respiratory mucosal vaccination is critically advantageous over systemic routes of vaccination against TB...

Research Grants78

  1. MYCOBACTERIAL GENES ANTIGENS AND VACCINES
    Barry Bloom; Fiscal Year: 2000
    ..in this competitive renewal application, they propose to develop effective and safe live attenuated tuberculosis vaccines by generating defined mutations in the M...
  2. DIETARY DEFICIENCIES AND TUBERCULOSIS VACCINE EFFICIENCY
    David McMurray; Fiscal Year: 2004
    ..New tuberculosis vaccines will be tested, ultimately, in malnourished humans...
  3. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2010
    ..William Hildebrand). The teams will perform vaccine evaluation, genetic re-construction and epitope discovery in a highly synergistic manner and boost our existing knowledge on anti-tuberculosis vaccines.
  4. Mechanisms of Mycobacterial Antigen Processing
    Chinnaswamy Jagannath; Fiscal Year: 2009
    ..William Hildebrand). The teams will perform vaccine evaluation, genetic re-construction and epitope discovery in a highly synergistic manner and boost our existing knowledge on anti-tuberculosis vaccines.
  5. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    CHERYL LIANE DAY; Fiscal Year: 2010
    ..fails in some infected individuals who progress to develop active tuberculosis disease;such studies will open up new avenues of research on immunotherapeutic interventions and the design of more effective tuberculosis vaccines.
  6. Mechanisms of Immune Regulation in Mycobacterium Tuberculosis Infection
    Cheryl Day; Fiscal Year: 2009
    ..fails in some infected individuals who progress to develop active tuberculosis disease; such studies will open up new avenues of research on immunotherapeutic interventions and the design of more effective tuberculosis vaccines.
  7. POPULATION-BASED MOLECULAR EPIDEMIOLOGY OF TUBERCULOSIS
    Philip Hopewell; Fiscal Year: 2000
    ..5) To use information from the study sites to develop approaches to the evaluation of candidate tuberculosis vaccines. Taken together this group of aims will serve to provide the epidemiologic basis for tuberculosis control ..
  8. LATENCY AND REACTIVATION TUBERCULOSIS
    William Bishai; Fiscal Year: 2002
    ..Appropriate animal models are critical to the successful development of tuberculosis vaccines, new drugs and better diagnostic tests for tuberculosis.
  9. LATENCY AND REACTIVATION TUBERCULOSIS
    YUKARI MANABE; Fiscal Year: 2006
    ..Appropriate animal models are critical to the successful development of tuberculosis vaccines, new drugs and better diagnostic tests for tuberculosis.
  10. Heat Shock Protein based vaccine for Tuberculosis
    ANNIE MO; Fiscal Year: 2003
    ..heat shock protein-peptide complexes to elicit T cell responses may address a shortcoming of traditional tuberculosis vaccines that primarily elicit antibody responses...
  11. Response Therapies for MDR-TB
    Ian Orme; Fiscal Year: 2007
    ..Safety testing issues, toxicology testing, and process development leading to GMP production are also planned for the later stages of this proposed program. ..
  12. STRATEGIES FOR TUBERCULOSIS VACCINE DEVELOPMENT AND SCRE
    Ian Orme; Fiscal Year: 2004
    ..abstract_text> ..
  13. CHRONIC TUBERCULOSIS--LATENT OR DYNAMIC
    Ian Orme; Fiscal Year: 2003
    ..In this latter endeavor we shall be assisted by highly qualified mycobacterial chemists from within the Mycobacteria Research Laboratories [MRL] at CSU. ..
  14. Chronic Tuberculosis: Latent or Dynamic
    Ian Orme; Fiscal Year: 2007
    ....
  15. Guinea pig model for TB vaccine evaluations
    Ian Orme; Fiscal Year: 2007
    ..of infected guinea pigs, The proposed studies are lengthy, and unavoidably expensive, but should provide a basic framework upon which a standardized procedure for efficacy and safety testing of new tuberculosis vaccines can be based.
  16. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2006
    ..The proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories at Colorado State University, as well as several eminent consultants and advisers. ..
  17. AGING AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 1993
    ..Using data gathered by these diverse procedures, it is anticipated that new important knowledge will be gained regarding the precise events which occur in the aged animal exposed to virulent pulmonary tuberculosis...
  18. DEFINED NATIVE ANTIGENS AND IMMUNITY TO TUBERCULOSIS
    Ian Orme; Fiscal Year: 2000
    ..As previously in this Program, the proposed work will draw upon the broad expertise of various members of the Mycobacteria Research Laboratories, CSU, as well as a number of highly qualified consultants/collaborators. ..
  19. AGING AND IMMUNITY IN TUBERCULOSIS
    Ian Orme; Fiscal Year: 2002
    ....
  20. GENE EXPRESSION OF M.TUBERCULOSIS WITHIN MACROPHAGES
    Kathleen McDonough; Fiscal Year: 2004
    ..This work will contribute to our understanding of the factors needed for the establishment of tuberculosis infection and disease and will identify potential targets for tuberculosis vaccines, therapeutics, and diagnostic purposes.
  21. Role of DAP12 in type 1 anti-mycobacterial immunity
    Zhou Xing; Fiscal Year: 2005
    ..We strongly believe that our studies will provide new insights into the mechanisms of type 1 anti-microbial immunity and novel targets for immune modulation. ..
  22. Human T Cell Antigens of Mycobacterium tuberculosis
    Steven Reed; Fiscal Year: 2009
    ..Finally, we will test antigens/vaccine formulations in rodent models of infection and disease. By the end of the funding period, we will have defined a second vaccine candidate for entry into clinical trials. ..
  23. Development & Manufacture of an MDR Tuberculosis Vaccine
    Steven Reed; Fiscal Year: 2005
    ..This will enable us to immediately proceed to human clinical trials after the end of the funding period. ..